Novartis AG
NVSNYSEHealthcare● Active
$149.16
+$0.76(+0.51%)
Market Cap$284.6B
P/E Ratio—
52W High$170.46
52W Low$112.34
Novartis AG (NVS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVS · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 28, 2026EPS Actual
$1.99
Est. $2.11 · -5.7%
Revenue
$13.11B
Est. $13.44B · -2.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 28, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
NVS reports quarterly as a NYSE-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.49B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.49B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 21, 2026 | $2.19 | — | — | — | $14.16B | — |
| ▼ Q2 FY2026 | Apr 28, 2026 | $2.11 | $1.99 | -5.7% | $13.11B | $13.44B | -2.4% |
| ▲ Q1 FY2026 | Feb 4, 2026 | $1.99 | $2.03 | +2.0% | $13.34B | $13.70B | -2.7% |
| — Q4 FY2025 | Oct 28, 2025 | $2.26 | $2.25 | -0.4% | $14.36B | $13.64B | +5.3% |
| ▲ Q3 FY2025 | Jul 17, 2025 | $2.38 | $2.42 | +1.7% | $14.28B | $13.94B | +2.5% |
| ▲ Q2 FY2025 | Apr 29, 2025 | $2.12 | $2.28 | +7.5% | $13.62B | $13.90B | -2.0% |
| ▲ Q1 FY2025 | Jan 31, 2025 | $1.80 | $1.98 | +10.0% | $13.56B | $12.84B | +5.6% |
| ▲ Q4 FY2024 | Oct 29, 2024 | $1.94 | $2.06 | +6.2% | $13.17B | $12.76B | +3.2% |
Q3 FY2026
Jul 21, 2026
EPS Actual
—
EPS Est.
$2.19
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 28, 2026Miss
EPS Actual
$1.99
EPS Est.
$2.11
EPS Surpr.
-5.7%
Revenue
$13.11B
Q1 FY2026
Feb 4, 2026Beat
EPS Actual
$2.03
EPS Est.
$1.99
EPS Surpr.
+2.0%
Revenue
$13.34B
Q4 FY2025
Oct 28, 2025
EPS Actual
$2.25
EPS Est.
$2.26
EPS Surpr.
-0.4%
Revenue
$14.36B
Q3 FY2025
Jul 17, 2025Beat
EPS Actual
$2.42
EPS Est.
$2.38
EPS Surpr.
+1.7%
Revenue
$14.28B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$2.28
EPS Est.
$2.12
EPS Surpr.
+7.5%
Revenue
$13.62B
Q1 FY2025
Jan 31, 2025Beat
EPS Actual
$1.98
EPS Est.
$1.80
EPS Surpr.
+10.0%
Revenue
$13.56B
Q4 FY2024
Oct 29, 2024Beat
EPS Actual
$2.06
EPS Est.
$1.94
EPS Surpr.
+6.2%
Revenue
$13.17B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $2.33 | $2.42 | $2.48 | 1 |
| Q3 FY2027 | $2.32 | $2.41 | $2.47 | 1 |
| Q2 FY2027 | $2.28 | $2.37 | $2.43 | 1 |
| Q1 FY2027 | $2.16 | $2.25 | $2.31 | 1 |
| Q4 FY2026 | $2.14 | $2.22 | $2.28 | 1 |
| Q3 FY2026 | $2.26 | $2.27 | $2.30 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $14.3B | $14.8B | $15.0B | 3 |
| Q3 FY2027 | $14.2B | $14.6B | $14.9B | 2 |
| Q2 FY2027 | $14.0B | $14.4B | $14.7B | 2 |
| Q1 FY2027 | $13.4B | $13.8B | $14.1B | 3 |
| Q4 FY2026 | $14.4B | $14.8B | $15.1B | 3 |
| Q3 FY2026 | $14.4B | $14.5B | $14.7B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 28, 2026 | -5.7% | $144.19 | $145.50 | +0.91% |
| ▲ Q1 FY2026 | Feb 4, 2026 | +2.0% | $149.86 | $152.91 | +2.04% |
| ▲ Q4 FY2025 | Oct 28, 2025 | -0.4% | $129.14 | $123.43 | -4.42% |
| ▲ Q3 FY2025 | Jul 17, 2025 | +1.7% | $118.37 | $114.52 | -3.25% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +7.5% | $112.63 | $113.45 | +0.73% |
| ▲ Q1 FY2025 | Jan 31, 2025 | +10.0% | $104.75 | $104.72 | -0.03% |
| ▲ Q4 FY2024 | Oct 29, 2024 | +6.2% | $115.63 | $110.53 | -4.41% |
| ▲ Q3 FY2024 | Jul 18, 2024 | +4.2% | $111.80 | $107.22 | -4.10% |
Q2 FY2026+0.91%
Report Date
Apr 28, 2026
EPS Beat/Miss
-5.7%
Price Before
$144.19
Price After
$145.50
Q1 FY2026+2.04%
Report Date
Feb 4, 2026
EPS Beat/Miss
+2.0%
Price Before
$149.86
Price After
$152.91
Q4 FY2025-4.42%
Report Date
Oct 28, 2025
EPS Beat/Miss
-0.4%
Price Before
$129.14
Price After
$123.43
Q3 FY2025-3.25%
Report Date
Jul 17, 2025
EPS Beat/Miss
+1.7%
Price Before
$118.37
Price After
$114.52
Q2 FY2025+0.73%
Report Date
Apr 29, 2025
EPS Beat/Miss
+7.5%
Price Before
$112.63
Price After
$113.45
Q1 FY2025-0.03%
Report Date
Jan 31, 2025
EPS Beat/Miss
+10.0%
Price Before
$104.75
Price After
$104.72
Q4 FY2024-4.41%
Report Date
Oct 29, 2024
EPS Beat/Miss
+6.2%
Price Before
$115.63
Price After
$110.53
Q3 FY2024-4.10%
Report Date
Jul 18, 2024
EPS Beat/Miss
+4.2%
Price Before
$111.80
Price After
$107.22
Avg Beat Reaction-1.92%
Avg Miss Reaction+0.91%
Beat Rate7 / 8 quarters
Largest Move-4.42% (Q4 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVS ends December
Novartis AG (NVS) most recently reported earnings on April 28, 2026 for Q2 FY2026, posting EPS of $1.99 — missing the analyst consensus of $2.11 by -5.7%. The next NVS earnings date is expected around September 1, 2026.
Each quarter, investors track NVS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVS earnings · 5 questionsNovartis AG's next earnings report is expected around September 1, 2026. NVS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVS historically reports after market close (AMC).
NVS earnings datewhen is NVS earningsNVS next earnings datewhen does NVS report earningsNVS earnings calendar
▸ Source: FMP · Novartis AG SEC filings · US GAAP · Novartis AG SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026